Telmisartan in Combination With Cytotoxic Regimens in Platinum-Resistant Ovarian Cancer

This study is testing whether adding a blood pressure drug called telmisartan to standard chemotherapy helps treat platinum-resistant ovarian cancer — cancer that has stopped responding to platinum-based chemotherapy drugs. Telmisartan is thought to affect cancer cell survival, and researchers want to see if it can make chemotherapy more effective. **You may be eligible if...** - You are 18 or older - You have high-grade serous ovarian cancer that is resistant or refractory to platinum chemotherapy (meaning it came back or grew within 6 months of your last platinum treatment) - You are in reasonable health (ECOG performance status 0–2) - You are scheduled to receive standard chemotherapy for ovarian cancer - You have a life expectancy of at least 2 months **You may NOT be eligible if...** - You have severe organ dysfunction or poor blood counts - You are pregnant or breastfeeding - You have uncontrolled infections Talk to your doctor to see if this trial is right for you.